
Nurulhuda Mustafa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/81197/publications.pdf Version: 2024-02-01



NUDULHUDA MUSTAFA

#	Article	IF	CITATIONS
1	T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. PLoS ONE, 2022, 17, e0261469.	2.5	Ο
2	Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. , 2021, 9, e002123.		8
3	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. European Journal of Medicinal Chemistry, 2019, 184, 111755.	5.5	15
4	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European Journal of Medicinal Chemistry, 2018, 158, 593-619.	5.5	33
5	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry, 2017, 60, 8336-8357.	6.4	82
6	VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. Oncotarget, 2017, 8, 101847-101864.	1.8	5
7	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. Journal of Medicinal Chemistry, 2016, 59, 8233-8262.	6.4	78